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ABSTRACT
Diffuse large B cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL), characterized by
a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histo-
pathologic and immunophenotypic evaluations. Recent studies have focused on the use of genome-scale expres-
sion profiles that provide a snap fingerprint of the tumor and identifying tumors with similar genetic alterations
and clinical features. Gene expression studies have the ability to recognize distinct subgroups of patients based
on similarmolecular characteristics andmarkedly different outcomes that were independent of the International
Prognostic Index (IPI). Further, DNAmicroarray studies also allow identification of new prognostic biomarkers
in DLBCL. However, new methods for immunohistochemical analysis of tissue microarray and RNA extraction
from paraffin-embedded blocks are required to overcome the major pitfall of this technology—the requirement
for fresh tissue.Herein, we summarize the progressmade in better prediction of prognosis ofDLBCLpatients as
a result of gene expression profiling.
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Diffuse large B cell lymphoma (DLBCL) is
the most common adult non-Hodgkin lymphoma
(NHL), with an annual incidence of .25,000 cases
in the United States [1]. Although DLBCL has charac-
teristic morphology, marked immunophenotypic, cy-
togenetic, and molecular heterogeneity underlies the
variable clinical outcome of DLBCL patients. Clinical
surrogates, such as the International Prognostic Index
(IPI) [2], although highly useful, do not adequately
capture the molecular and cellular variability that af-
fects clinical behavior of DLBCL. Biologic mecha-
nisms underlying DLBCL pathogenesis are complex,
and involve intricate relationships between multiple
genes, signaling pathways, and regulatory processes
[3]. Elucidation of DLBCL pathogenesis is necessary
to allow recognition of new molecular therapeutic tar-
gets, discovery of DLBCL subgroups with distinct
clinical outcomes, and identification of molecular
prognostic markers that may more accurately predict
DLBCL outcomes. Accomplishment of these goals is108of paramount importance, and may form the basis
for future risk-adapted treatments. Historically,
attempts to elucidate DLBCL pathogenesis or identify
new prognostic markers utilized a single gene ap-
proach. However, the latter cannot account for the
complex multigene processes underlying DLBCL
pathogenesis, and thus do not accurately reflect the
complex changes observed in these tumors. Conse-
quently, new investigational tools enabling simulta-
neous evaluation of multiple components of these
biologic processes might further advance our under-
standing of DLBCL and potentially lead to specific
molecularly targeted and patient-tailored therapies.
DNA microarrays are a new technology used
to measure the expression of tens of thousands of
genes simultaneously, enabling a more comprehensive
evaluation of gene expression. This technique allows
the comprehensive analysis of messenger RNA
(mRNA) expression in tumor samples. The clinical
characteristics and behavior of a tumor are determined
by the specific genetic changes present in the tumor
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expression creating a ‘‘molecular signature’’ or ‘‘finger-
print’’ for the tumor. The full potential of microarrays
has not yet been realized; however, they may (1) iden-
tify previously unrecognized disease entities with dis-
tinct biologic and clinical features, (2) elucidate the
key genetic profiles and lesions that define each of
these new nosologic entities, (3) discover new molecu-
lar targets for future therapeutic intervention, (4) iden-
tify genes that play a potential role in determining
prognosis, (5) discover previously unknown genes of
major clinical relevance from numerous EST clones
present on the arrays, and (6) identify gene expression
signatures correlated with response to specific thera-
peutic agents. Herein, we briefly review the contribu-
tion of gene expression profiling and its role in
prediction of outcome of DLBCL patients.
Less than half of the patients with DLBCL will be
cured with conventional chemotherapy regimens [4,5].
Improvement in disease-free and overall survival
(DFS, OS) may be obtained with the addition of
monoclonal antibodies (mAb), such as rituximab [5].
Although standard pathologic techniques do not reli-
ably predict sensitivity to chemotherapy or outcome
for individual patients, gene expression profiling has
provided important insights into the biology of
DLBCL, allowing a better molecular classification of
tumors that are more homogeneous in pathogenesis
and clinical behavior.
The pivotal microarray study was performed by
Alizadeh et al. [6] with the use of a cDNALymphochip
array. The evaluation of tumors from 42 DLBCL pa-
tients treated with anthracycline-based chemotherapy
led to the identification of 2 distinct subgroups based
on the expression of genes characteristic of germinal
center B cells (GC) or in vitro-activated peripheral
blood B cells (ABC). Patients with GC subtype had
a significantly better 5-year OS (76% versus 16%,
P\ .01), independent of the IPI score. These findings
were further confirmed by the larger Lymphoma and
Leukemia Molecular Profile Project (LLMPP) study
[7]. Using a similar cDNA Lymphochip array plat-
form, analysis of tumor samples from 240 DLBCL pa-
tients treated with anthracycline-based chemotherapy
demonstrated a significant difference in the 5-year
OS between the GC-like and ABC-like subgroups
(60% versus 35%, respectively). Although the early
microarray expression profile studies were able to
identify the presence of biologically distinct subgroups
of DLBCL, they were unable to identify the rela-
tive contribution of individual genes, therefore mak-
ing it difficult to build clinically useful prognostic
models based on a relatively small number of genes.
To address this question, both the Rosenwald [7]
and Shipp groups [8] applied supervised analytic
methodologies to the Lymphochip and Affymetrix-
derived gene expression profiles of 240 and 58DLBCLpatients, respectively. This approach led to construc-
tion of outcome predictors based on expression of
17 and 13 genes, respectively. However, there was no
overlap between the lists of genes comprising these
2 outcome prediction models. This disparity between
large genome-scale expression profile models has
been attributed to patient selection, technical differ-
ences, arrays composition, and variable analytical ap-
proaches. Wright et al. [9] designed a method based
on Bayes’ rule that could be used to translate experi-
mental results across different microarray platforms.
Expression data from 14 genes identified by the
LLMPP [7] and analyzed by Shipp et al. [8] were able
to subdivide patients into GC-like and ABC-like,
with significant different outcomes. Nevertheless, de-
spite the positive results, this model may not be clini-
cally useful because of complex manipulations with
shifting and scaling of gene expression fromAffymetrix
data tomatch themean and variance of the correspond-
ing expression values in the cDNA microarray dataset.
In an attempt to devise a technically simplemethod
that could be applicable for routine clinical use, we
evaluated themRNA expression of 36 genes previously
reported to predict survival [10] in tumor specimens
from 66 DLCBL patients treated with anthracycline-
based therapy. The top 6 genes ranked according to
their predictive power on univariate analysis were
used to construct a model based on their relative indi-
vidual contribution into a multivariate analysis.
Among the selected genes, LMO2, BCL-6, and FN1
predicted longer survival, whereas CCND2, SCYA3,
and BCL-2 predicted shorter survival. Based on the ex-
pression of these 6 genes, patients could be subdivided
into IPI-independent low-, intermediate-, and high-
risk groups with significantly different 5-year OS rates
ranging from 65% in the low-risk to 15% in the high-
risk subgroups. This model was subsequently validated
in the data sets available from previously reported
studies [7,8].
However, gene expression arrays are not widely
available, require fresh tumor specimens, and are la-
bor-intensive and expensive. Therefore, researchers
have tried to use the information derived from RNA
profiling studies to create prediction models based
on more amenable techniques such as immunohisto-
chemistry (IHC). However, multiple IHC studies
have led to contradictory results [11,12], suggesting
the lack of an ideal set of IHC markers for outcome
prediction in DLBCL. Hans et al. [13] complimented
cDNA microarrays with immunohistochemistry
(IHC) staining. They proposed an IHC model based
on 3 markers: CD10, BCL-6, and MUM1 for determi-
nation of GC-like and ABC-like DLBCL subtypes.
This model demonstrated positive predictive values
of 87% and 73% for correctly identifying GC-like
and ABC-like DLBCL subtypes and could predict pa-
tient survival: 76% of IHC-defined GC-like DLBCL
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patients. However, comparison of this IHC model
with the gold- standard gene expression profiling re-
vealed a 20% misclassification rate, suggesting the
need for incorporation of additional IHC markers to
improve the predictive value of this model. Because an-
tibodies are not available for many of the GC-specific
genes, novel mAb directed to newly identified RNA-
based prognostic biomarkers need to be generated
and assessed in the future IHC-based prediction
models [14,15]. Furthermore, although IHC is used
routinely in diagnostic laboratories, its applicability
for outcome prediction requires standard methods
for tissue fixation, antigen retrieval protocols and
staining methodologies, a uniform use of the same an-
tibodies directed to a specific epitope on the target
protein, and application of identical predetermined
thresholds to define positivity for specific antibodies.
This information, however, is currently unavailable.
Alternatively, it is possible to construct predictive
models based on RNA-based gene expression profiling
in formalin-fixed paraffin-embedded tissues, which are
used routinely for IHC and thus are widely available.
Unfortunately, the process of formalin fixation may
contribute to RNA degradation and modification
that limits the extractability of high-quality RNA by
routine methods. Recent improvements in RNA ex-
traction protocols have allowed the extraction of short
informative RNA fragments from paraffin blocks, with
potential use in RNA quantification [16]. We have re-
cently developed an optimized methodology for RNA
extraction from formalin fixed, paraffin-embedded
lymphoid tissues [17]. Applicability of this new
methodology in DLBCL patients is currently under
investigation.
In addition, it is important to recognize that the
usefulness of prognostic factors or models may de-
pend on the specific clinical setting and therapeutic
approach. Almost all of the previous studies were per-
formed in newly diagnosed DLBCL patients in the
pre-rituximab era. Improved survival with the addi-
tion of rituximab to chemotherapy might be associ-
ated with a change in the predictive value of clinical
and/or biologic markers, resulting in the loss of prog-
nostic power of previously established markers or the
discovery of new, previously unidentified predictors
[18,19]. Therefore, the predictive value of the previ-
ously established risk factors should be reevaluated
and new factors identified for patients treated with ri-
tuximab-based chemotherapy. Further, there are no
well established prognostic biomarkers that can reli-
ably predict survival of DLBCL patients following
hematopoietic stem cell transplantation (HSCT).
About 40% of primary resistant or relapsed DLBCL
patients may be cured with autologous HSCT, but
gene expression profiling studies or biomarker studies
were not performed in these patients. Recently, Mos-kowitz et al. [20] evaluated whether the cell of origin
in repeat biopsies before autologous HSCT may pre-
dict patient survival. An IHC model proposed by
Hans et al. [13] was applied to biopsies from 88 trans-
plantation-eligible patients with relapsed or primary
refractory DLBCL undergoing ifosfamide, carbopla-
tin, etoposide (ICE) second-line chemotherapy
(SLT) followed by high-dose therapy (HDT) and au-
tologous HCT. There was no significant difference in
event-free survival (EFS) or OS based on the cell of
origin or any of the common pathologic markers ex-
amined. Whether these findings suggest that distinct
cell of origin is not associated with outcome in pa-
tients undergoing HDT and autologous HCT or sim-
ply was because of poor reproducibility of this model
in newly diagnosed untreated DLBCL patients (Nat-
kunam and Lossos, unpublished observations), is
presently unknown. Further studies are needed in
this patient population. Of note, the IHC-defined
GC phenotype was correlated with improved survival
in high-risk DLBCL patients treated with autologous
HCT as first-line therapy [21].
SUMMARY
In conclusion, microarrays are powerful tools for
discovery and hypothesis generation, allowing re-
searchers to obtain an unbiased survey of gene expres-
sion in lymphoma samples. These studies allowed
subclassification of DLBCL into distinct subtypes
with different pathogenesis and prognosis. Further-
more, these studies also enabled identification of new
prognostic biomarkers and models in these tumors.
However, the ‘‘prime time’’ for their incorporation
into routine clinical practice has not arrived yet. Con-
tinuous research will address the remaining hurdles to
allow future routine use of prognostic biomarkers in
daily Oncology practice. These advances will have sig-
nificant implications for design of clinical trials and
development of new therapeutic approaches.
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